Suryoday Small Finance Bank Fund Raise of ₹300 Cr

Suryoday Small Finance Bank Earnings Call Transcript: Key Takeaways

Suryoday SFB reported strong asset quality improvement and growth, though NIM remained flat despite windfall insurance claims.

Call

Guides 32% growth

Suryoday Small Finance Bank Investor Presentation: Key Takeaways

Suryoday SFB reported strong Q2FY27 performance with PAT growing 151.7% YoY. Focus continues on pivoting towards individual loans and retail assets which now comprise 59.2% of the mix.

Suryoday Small Finance Bank Management Change

Suryoday Small Finance Bank announced that Mr. Ranjit Jayant Shah, Non-Executive Non-Independent Director, will cease to hold office effective November 2, 2026, upon tenure completion.

Suryoday Small Finance Bank Results Update

Suryoday Small Finance Bank released a press release on its unaudited Q2 and H1 FY27 results. The release highlights profit after tax of Rs.151.7 Cr for H1 FY27, up 131% year on year.

Suryoday Small Finance Bank Q2 FY27 Results: Net Profit ₹76.5 Cr, Up 151.6% YoY

Suryoday Small Finance Bank Ltd reported revenue from operations of ₹702.9 Cr (+35.3% YoY) and net profit of ₹76.5 Cr (+151.6% YoY) for Q2 FY27.

Key figure

Net profit ₹76.5 Cr · +151.6% YoY

Suryoday Small Finance Bank Debt & Borrowing: ₹100 Cr

Suryoday Small Finance Bank's board approved the issuance of up to Rs. 100 Crore in unsecured, subordinated Lower Tier II Non-Convertible Debentures.

Value

₹100.0 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.

Gujarat Inject (Kerala) Fund Raise of ₹3 Cr

Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.

Value

₹3.00 Cr